Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed malignancy
• * Metastatic or unresectable disease
• * Standard curative or palliative measures do not exist, are no longer effective, have been completed, or have been refused
• CEA-positive tumor (either by immunohistochemistry or as demonstrated by elevated CEA \> 50 μg/L)
• No primary brain tumor or brain metastases
• PATIENT CHARACTERISTICS:
• WHO performance status 0-1
• Life expectancy ≥ 3 months
• Hemoglobin ≥ 10 g/dL
• Platelet count ≥ 100 x 10\^9/L
• Neutrophil count ≥ 2.0 x 10\^9/L
• Lymphocyte count ≥ 1.0 x 10\^9/L
• Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)
• ALT/AST ≤ 5 times ULN
• Alkaline phosphatase ≤ 5 times ULN
• Calculated creatinine clearance OR isotope clearance measurement ≥ 50 mL/min
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception 4 weeks prior to, during, and for 6 months after completion of study therapy (male patients must use barrier-method contraception)
• LVEF ≥ 50% on MUGA scan (for patients receiving cyclophosphamide)
• ECG and exercise ECG (or stress ECHO) normal (may be abnormal but not clinically significant)
• Urine dipstick normal (may be abnormal but not clinically significant)
• No medical high risk due to nonmalignant systemic disease including active uncontrolled infection
• No known serologically positive hepatitis B, hepatitis C, HIV, or HTLV
• No history of autoimmune disease
• No inflammatory bowel disease
• No concurrent congestive heart failure or prior history of NYHA class III-IV cardiac disease
• No concurrent malignancies originating from other primary sites, except for adequately treated cone-biopsied carcinoma in situ of the cervix uteri or basal cell or squamous cell carcinoma of the skin
• No other condition that, in the investigator's opinion, would make the patient an unsuitable candidate for the clinical trial
• PRIOR CONCURRENT THERAPY:
• At least 30 days since prior and no concurrent participation in another clinical trial
• At least 4 weeks since prior and no concurrent radiotherapy (except for palliative reasons \[i.e., control of bone pain\])
• At least 4 weeks since prior and no concurrent endocrine therapy, immunotherapy, or chemotherapy (6 weeks for nitrosoureas and mitomycin C)
• No toxic manifestations of previous treatment, except for alopecia or certain grade 1 toxicities that, in the opinion of the investigator and CRUK (Cancer Research UK), would exclude the patient (e.g., grade 1 neuropathy or grade 1 fatigue)
• No prior major thoracic and/or abdominal surgery from which the patient has not yet recovered
• No prior bone marrow transplant or extensive radiotherapy to \> 25% of bone marrow
• No concurrent systemic steroids or other immunosuppressive therapy
• No other concurrent anticancer therapy or investigational drugs